Pem_Axi, a humanized anti-PD-1 monoclonal antibody, is the first anti-PD-1 agent to improve overall survival and progression-free survival in the first-line treatment of renal cell carcinoma [18]. The gene discussed is PDCD1; the disease is renal cell carcinoma.